Partial summary of immunotherapy clinic trials in hematologic malignancies.
| Author . | Disease . | Patient Population . | Immune Intervention . | Response . | Ref . |
|---|---|---|---|---|---|
| Abbreviations: FL, follicular lymphoma; Id, idiotype protein; KLH, keyhole limpet hemocyanin; CR, complete response; MM, multiple myeloma; DTH, delayed type hypersensitivity; CML, chronic myeloid leukemia; PBSCT, peripheral blood stem cell transplant; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; Ad, adenovirus; NHL, non-Hodgkin’s lymphoma | |||||
| Bendandi | FL | CR | Id-KLH Vaccine | 8/11 molecular CRs | 2 |
| Rassmussen | MM | Stage I | Id-IL-12 ± GM-CSF | 4/6 reduced tumor burden (3/4 anti-Id Tcell response) | 3 |
| Massaia | MM | Auto-PBSCT | Id-KLH, GM-CSF v IL-2 | anti-Id DTH response 8/10 | 25 |
| Reichardt | MM | Auto-PBSCT | Id-DC | 2/12 anti-Id T cell proliferation 1/3 anti-Id CTL response | 15 |
| Cathcart | CML | Multi-valent bcr/abl fusion peptide | + peptide-specific response | 4 | |
| Bocchia | CML | Residual cytogenetic disease | Bcr/abl fusion peptide | 7/15 cytogenetic CR 3 molecular CR | 5 |
| Borrello | MM | autoPBSCT | Autologous tumor and GM-CSF–producing bystander cell line | 6/16 CRs 3/16 with M-spike declines post-BMT | 26 |
| Borrello | AML | CR prior to auto-PBSCT | Autologous tumor and GM-CSF–producing bystander cell line | 12/18 reduction in WT-1 transcript in marrow with pre-transplant vaccination | 27 |
| Hsu | FL | Id-DC | 1/4 molecular CR 1/4 complete tumor regression | 14 | |
| Timmerman | FL | Residual disease | Id-DC | 70% response rate in 35 pts | 1 |
| Titzer | MM | Heavily pretreated | Id-DC followed by Id-DC or Id-GM-CSF | 4/10 reduction in bone marrow plasma cell infiltrate | 16 |
| Wierda | CLL | Progressive intermediate/high risk CLL | Ad-CD154-transfected | Reduction in CLL burden autologous CLL cells | 23 |
| Laport | NHL | Relapsed/refractory | Anti-CD3/CD28 activated PBL | 5/16 CR 7/16 PR | 24 |
| Author . | Disease . | Patient Population . | Immune Intervention . | Response . | Ref . |
|---|---|---|---|---|---|
| Abbreviations: FL, follicular lymphoma; Id, idiotype protein; KLH, keyhole limpet hemocyanin; CR, complete response; MM, multiple myeloma; DTH, delayed type hypersensitivity; CML, chronic myeloid leukemia; PBSCT, peripheral blood stem cell transplant; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; Ad, adenovirus; NHL, non-Hodgkin’s lymphoma | |||||
| Bendandi | FL | CR | Id-KLH Vaccine | 8/11 molecular CRs | 2 |
| Rassmussen | MM | Stage I | Id-IL-12 ± GM-CSF | 4/6 reduced tumor burden (3/4 anti-Id Tcell response) | 3 |
| Massaia | MM | Auto-PBSCT | Id-KLH, GM-CSF v IL-2 | anti-Id DTH response 8/10 | 25 |
| Reichardt | MM | Auto-PBSCT | Id-DC | 2/12 anti-Id T cell proliferation 1/3 anti-Id CTL response | 15 |
| Cathcart | CML | Multi-valent bcr/abl fusion peptide | + peptide-specific response | 4 | |
| Bocchia | CML | Residual cytogenetic disease | Bcr/abl fusion peptide | 7/15 cytogenetic CR 3 molecular CR | 5 |
| Borrello | MM | autoPBSCT | Autologous tumor and GM-CSF–producing bystander cell line | 6/16 CRs 3/16 with M-spike declines post-BMT | 26 |
| Borrello | AML | CR prior to auto-PBSCT | Autologous tumor and GM-CSF–producing bystander cell line | 12/18 reduction in WT-1 transcript in marrow with pre-transplant vaccination | 27 |
| Hsu | FL | Id-DC | 1/4 molecular CR 1/4 complete tumor regression | 14 | |
| Timmerman | FL | Residual disease | Id-DC | 70% response rate in 35 pts | 1 |
| Titzer | MM | Heavily pretreated | Id-DC followed by Id-DC or Id-GM-CSF | 4/10 reduction in bone marrow plasma cell infiltrate | 16 |
| Wierda | CLL | Progressive intermediate/high risk CLL | Ad-CD154-transfected | Reduction in CLL burden autologous CLL cells | 23 |
| Laport | NHL | Relapsed/refractory | Anti-CD3/CD28 activated PBL | 5/16 CR 7/16 PR | 24 |